July 30th, 2014
Marathon Pharmaceuticals today announced Jeanine M. Swalec has joined the company as its vice president of regulatory affairs.
Swalec, 45, most recently served as the senior director for global regulatory affairs for Lundbeck Pharmaceuticals, which acquired Ovation Pharmaceuticals in 2009. Her 11-year career there began with Ovation Pharmaceuticals, where she directed development programs from pre-Investigational New Drug (IND) applications through New Drug Applications (NDAs) for marketing approvals. Under Swalec’s leadership, the company attained FDA approval for the anti-epileptic drugs Sabril® (vigabatrin) and Onfi® (clobazam), which are primarily used to treat pediatric patients with orphan diseases.
In her new position at Marathon, Swalec is charged with oversight of regulatory activities and securing registration of new chemical entities and extensions of marketed products. She is also responsible for diligence activities for potential product acquisitions and proactively addressing regulatory changes.
“Jeanine works effectively with regulators and has extensive experience guiding drug development processes. She is deeply committed to our mission of getting medicine to patients who need it and will help our team achieve its goal of delivering treatments where none currently exist,” said Dr. Tim Cunniff, Marathon Pharmaceuticals executive vice president for research and development.
Swalec began her career at Parke-Davis Pharmaceuticals and holds a degree in biology and chemistry from Eastern Michigan University. She is a member of the Drug Information Association and the Healthcare Businesswomen’s Association (HCA).